These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1363 related items for PubMed ID: 29181556

  • 21. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
    Lawal IO, Ankrah AO, Mokgoro NP, Vorster M, Maes A, Sathekge MM.
    Prostate; 2017 Aug; 77(11):1205-1212. PubMed ID: 28649735
    [Abstract] [Full Text] [Related]

  • 22. Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography for Prostate Cancer: Distribution of Disease and Implications for Radiation Therapy Planning.
    Gupta SK, Watson T, Denham J, Shakespeare TP, Rutherford N, McLeod N, Picton K, Ainsworth P, Bonaventura T, Martin JM.
    Int J Radiat Oncol Biol Phys; 2017 Nov 01; 99(3):701-709. PubMed ID: 29280465
    [Abstract] [Full Text] [Related]

  • 23. PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: Is there value beyond localization of disease?
    Küper AT, Kersting D, Telli T, Herrmann K, Rominger A, Afshar-Oromieh A, Lopes L, Karkampouna S, Shi K, Kim M, Hadaschik B, Darr C, Umutlu L, Fendler WP, Seifert R.
    Theranostics; 2024 Nov 01; 14(9):3623-3633. PubMed ID: 38948055
    [Abstract] [Full Text] [Related]

  • 24. Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer.
    Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG.
    J Nucl Med; 2018 Nov 01; 59(11):1714-1721. PubMed ID: 29653978
    [Abstract] [Full Text] [Related]

  • 25. The influence of 68Ga-prostate-specific membrane antigen PET/computed tomography on prostate cancer staging and planning of definitive radiation therapy.
    Al-Ibraheem A, Abuhijla F, Salah S, Shahait M, Khader J, Mohamad I, Al-Rasheed U, Pomykala KL, Herrmann K, Abu-Hijlih R.
    Nucl Med Commun; 2021 Jul 01; 42(7):811-817. PubMed ID: 33660693
    [Abstract] [Full Text] [Related]

  • 26. The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates.
    Scarpa L, Buxbaum S, Kendler D, Fink K, Bektic J, Gruber L, Decristoforo C, Uprimny C, Lukas P, Horninger W, Virgolini I.
    Eur J Nucl Med Mol Imaging; 2017 May 01; 44(5):788-800. PubMed ID: 28083690
    [Abstract] [Full Text] [Related]

  • 27. Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study.
    Dewes S, Schiller K, Sauter K, Eiber M, Maurer T, Schwaiger M, Gschwend JE, Combs SE, Habl G.
    Radiat Oncol; 2016 May 26; 11():73. PubMed ID: 27229485
    [Abstract] [Full Text] [Related]

  • 28. Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer.
    Nikitas J, Castellanos Rieger A, Farolfi A, Seyedroudbari A, Kishan AU, Nickols NG, Steinberg ML, Valle LF, Rettig M, Czernin J, Calais J.
    J Nucl Med; 2024 Sep 03; 65(9):1387-1394. PubMed ID: 39089811
    [Abstract] [Full Text] [Related]

  • 29. Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapy.
    Harsini S, Wilson D, Saprunoff H, Allan H, Gleave M, Goldenberg L, Chi KN, Kim-Sing C, Tyldesley S, Bénard F.
    Cancer Imaging; 2023 Mar 17; 23(1):27. PubMed ID: 36932416
    [Abstract] [Full Text] [Related]

  • 30. Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer.
    Harsini S, Martineau P, Plaha S, Saprunoff H, Chen C, Bishop J, Tyldesley S, Wilson D, Bénard F.
    Cancer Imaging; 2024 Aug 30; 24(1):117. PubMed ID: 39210431
    [Abstract] [Full Text] [Related]

  • 31. A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging.
    McCarthy M, Francis R, Tang C, Watts J, Campbell A.
    Int J Radiat Oncol Biol Phys; 2019 Jul 15; 104(4):801-808. PubMed ID: 30890448
    [Abstract] [Full Text] [Related]

  • 32. 68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer.
    Vinsensia M, Chyoke PL, Hadaschik B, Holland-Letz T, Moltz J, Kopka K, Rauscher I, Mier W, Schwaiger M, Haberkorn U, Mauer T, Kratochwil C, Eiber M, Giesel FL.
    J Nucl Med; 2017 Dec 15; 58(12):1949-1955. PubMed ID: 28637799
    [Abstract] [Full Text] [Related]

  • 33. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
    Kabasakal L, Demirci E, Nematyazar J, Akyel R, Razavi B, Ocak M, Aygun A, Obek C, Kural AR.
    Nucl Med Commun; 2017 Feb 15; 38(2):149-155. PubMed ID: 27893589
    [Abstract] [Full Text] [Related]

  • 34. Is there a nonnegligible effect of maximum standardized uptake value in the staging and management of prostate cancer with 68Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography imaging? A single-center experience.
    Ekmekcioglu O, Yavuzsan AH, Arican P, Kirecci SL.
    J Cancer Res Ther; 2021 Feb 15; 17(6):1351-1357. PubMed ID: 34916365
    [Abstract] [Full Text] [Related]

  • 35. Biochemical Persistence of Prostate-Specific Antigen After Robot-Assisted Laparoscopic Radical Prostatectomy: Tumor Localizations Using PSMA PET/CT Imaging.
    Meijer D, Donswijk ML, Bodar YJL, van Leeuwen PJ, Poel HGV, Vogel WV, Nieuwenhuijzen JA, Hendrikse NH, Oprea-Lager DE, Vis AN.
    J Nucl Med; 2021 Jul 01; 62(7):961-967. PubMed ID: 33158904
    [Abstract] [Full Text] [Related]

  • 36. Comparison of 68Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology.
    Zamboglou C, Drendel V, Jilg CA, Rischke HC, Beck TI, Schultze-Seemann W, Krauss T, Mix M, Schiller F, Wetterauer U, Werner M, Langer M, Bock M, Meyer PT, Grosu AL.
    Theranostics; 2017 Jul 01; 7(1):228-237. PubMed ID: 28042330
    [Abstract] [Full Text] [Related]

  • 37. PSMA-PET guided dose-escalated volumetric arc therapy (VMAT) for newly diagnosed lymph node positive prostate cancer: Efficacy and toxicity outcomes at two years.
    Shakespeare TP, Eggert E, Wood M, Westhuyzen J, Turnbull K, Rutherford N, Aherne N.
    Radiother Oncol; 2019 Dec 01; 141():188-191. PubMed ID: 31668514
    [Abstract] [Full Text] [Related]

  • 38. Patterns of Progression After 68Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for Recurrent Prostate Cancer.
    Soldatov A, von Klot CAJ, Walacides D, Derlin T, Bengel FM, Ross TL, Wester HJ, Derlin K, Kuczyk MA, Christiansen H, Henkenberens C.
    Int J Radiat Oncol Biol Phys; 2019 Jan 01; 103(1):95-104. PubMed ID: 30201438
    [Abstract] [Full Text] [Related]

  • 39. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of 68Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer.
    Hofman MS, Eu P, Jackson P, Hong E, Binns D, Iravani A, Murphy D, Mitchell C, Siva S, Hicks RJ, Young JD, Blower PJ, Mullen GE.
    J Nucl Med; 2018 Apr 01; 59(4):625-631. PubMed ID: 28986512
    [Abstract] [Full Text] [Related]

  • 40. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
    van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B, Nguyen Q, Ho B, Emmett L.
    BJU Int; 2016 May 01; 117(5):732-9. PubMed ID: 26683282
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 69.